Cerebral: Who It's Best For and Ideal Patient Profile

What Cerebral Actually Offers

Cerebral is a subscription telehealth platform that pairs patients with prescribers (nurse practitioners, physician assistants, or psychiatrists) and, optionally, therapists for common mental health conditions. The company launched in January 2020, grew rapidly during the COVID-19 pandemic, and by mid-2022 reported over 700,000 cumulative patients served.

The platform operates on a tiered monthly subscription. The lowest tier ($85/month) covers medication management only: an initial psychiatric evaluation, ongoing prescriber check-ins, and prescription delivery to a local pharmacy. The middle tier ($185/month) adds care counseling sessions. The top tier ($325/month) bundles prescriber visits with licensed therapy. Insurance can reduce these costs substantially, though reimbursement depends on the carrier and state.

A 2022 analysis published in JAMA Network Open found that telehealth psychiatric visits increased 16.4-fold between 2019 and 2022, with platforms like Cerebral driving much of that adoption [1]. The rapid scale-up raised questions about prescribing quality, particularly around stimulants and benzodiazepines. Cerebral's own internal policy changes since late 2022 reflect those concerns. The company stopped prescribing controlled substance Class II stimulants in some states before partially resuming under tighter protocols.

For patients seeking straightforward SSRI or SNRI management for generalized anxiety disorder (GAD) or major depressive disorder (MDD), Cerebral's model removes geographic and scheduling barriers common to traditional psychiatry. The American Psychiatric Association's 2024 position statement on telepsychiatry affirmed that synchronous video visits produce clinical outcomes comparable to in-person care for most mood and anxiety disorders [2].

The Ideal Cerebral Patient

The patient who gets the most value from Cerebral is an adult (18+) with a single or dual diagnosis of anxiety, depression, or ADHD who primarily needs medication titration and periodic check-ins. This is someone whose symptoms are mild to moderate in severity. Think of the working professional who cannot take half a day off for an in-person psychiatry appointment, or the rural patient whose nearest prescriber is 90 minutes away.

Cerebral works best when three conditions align: the diagnosis is within the platform's prescribing scope, the patient is stable enough for brief telehealth visits (typically 15 minutes for follow-ups), and the patient does not require intensive psychotherapy or crisis intervention. Patients with treatment-resistant depression, active psychosis, severe personality disorders, or eating disorders with medical instability should seek a higher level of care.

The PHQ-9, which Cerebral uses as a screening measure for depression severity, has a validated sensitivity of 88% and specificity of 88% for detecting major depression at a cutoff score of 10 or above [3]. This tool works well in a telehealth setting for initial screening. It does not, however, replace a thorough diagnostic interview for complex presentations.

A 2023 cross-sectional study in Psychiatric Services examined diagnostic concordance between initial telehealth assessments and subsequent in-person evaluations across multiple platforms. The study reported 78% agreement for single-diagnosis anxiety or depression but only 54% agreement for comorbid conditions involving personality pathology or substance use disorders [4]. Patients with more layered presentations may benefit from a traditional intake process.

ADHD Prescribing: Where the Controversy Lives

Cerebral's ADHD services attracted significant scrutiny in 2022, when reports surfaced that some prescribers were diagnosing ADHD after brief video assessments and prescribing stimulants without adequate baseline evaluation. The U.S. Department of Justice opened an investigation into the company's controlled substance practices, and Cerebral responded by implementing mandatory multi-session evaluations before stimulant initiation in most states.

The 2024 American Professional Society of ADHD and Related Disorders (APSARD) consensus statement recommends that adult ADHD diagnosis include a clinical interview lasting at least 30 minutes, corroborating history from a secondary informant when possible, and at least one validated rating scale such as the Adult ADHD Self-Report Scale (ASRS-v1.1) [5]. Whether Cerebral's current protocol fully meets this standard depends on the individual clinician and state.

For patients with a well-established ADHD diagnosis who need ongoing stimulant management, Cerebral can function as a convenient maintenance prescriber. The platform's value drops sharply for first-time ADHD evaluations, where diagnostic accuracy depends on time-intensive assessment. The ASRS-v1.1 screener has a sensitivity of 68.7% and specificity of 99.5% in primary care populations [6], but screening alone without a detailed history risks both overdiagnosis and missed comorbidities.

If you already carry a confirmed ADHD diagnosis and have stable stimulant dosing, transferring care to Cerebral for refills and periodic check-ins is reasonable. If you suspect ADHD but have never been formally evaluated, a comprehensive neuropsychological assessment through a specialist will yield more reliable results.

Anxiety and Depression: The Strongest Use Case

Cerebral's core competency is prescribing first-line pharmacotherapy for GAD and MDD. SSRIs (sertraline, escitalopram, fluoxetine) and SNRIs (venlafaxine, duloxetine) remain the first-line pharmacologic treatment per the APA's 2024 Practice Guideline Update for Major Depressive Disorder [7]. These medications do not require in-person monitoring for most patients and carry minimal abuse potential.

The STAR*D trial (N=2,876) established that approximately 33% of MDD patients achieve remission with the first SSRI trial, and cumulative remission reaches about 67% after two sequential medication trials [8]. This means many patients will need at least one medication switch or augmentation. Cerebral's model supports this through follow-up visits every 4 to 8 weeks during titration, which aligns with guideline-concordant care.

For anxiety specifically, a Cochrane review of 101 trials (N=25,441) found SSRIs and SNRIs effective for GAD, social anxiety disorder, panic disorder, and PTSD, with number-needed-to-treat values ranging from 4 to 8 depending on the specific condition [9]. The evidence supports remote prescribing for these indications, provided the prescriber conducts adequate safety screening (suicidality risk, bipolar screening before antidepressant initiation, drug interaction review).

Where Cerebral's model strains is therapy delivery. The platform's therapists are often licensed counselors rather than doctoral-level psychologists, and session frequency is typically biweekly rather than weekly. For patients who need structured cognitive-behavioral therapy (CBT) with weekly sessions, a dedicated therapy practice or a platform specializing in therapy (such as BetterHelp's structured CBT programs) may deliver better outcomes. A meta-analysis in The Lancet Psychiatry of 155 randomized trials (N=15,191) found that weekly CBT sessions produced a standardized mean difference of 0.75 for depression outcomes, while sessions spaced more than 2 weeks apart dropped to 0.47 [10].

Cost and Insurance: What to Expect

Cerebral's pricing structure has shifted multiple times since launch. As of early 2026, the company accepts insurance from major carriers including Aetna, Cigna, Anthem, and many Blue Cross Blue Shield plans. For insured patients, the out-of-pocket cost often reduces to a standard specialist copay ($20 to $60 per visit) rather than the full subscription price.

Uninsured patients face the subscription tiers outlined above. Compared to national averages, this pricing is competitive. The 2024 FAIR Health Consumer report found that the median out-of-pocket cost for an initial psychiatric evaluation in the U.S. was $284, with follow-up medication management visits averaging $178 [11]. Cerebral's $85/month medication-management plan includes both an initial evaluation and monthly follow-ups, which undercuts the per-visit cost for patients paying cash.

The hidden cost variable is pharmacy pricing. Cerebral prescribes to external pharmacies, and the patient bears the cost of the medication itself. Generic SSRIs are inexpensive ($4 to $15/month at most pharmacies). Brand-name ADHD stimulants like Vyvanse can exceed $300/month without insurance. Cerebral does not operate its own pharmacy, so patients should use GoodRx or their insurance formulary to manage medication costs separately.

Cerebral vs. Alternatives: A Direct Comparison

The telehealth mental health space now includes Done (ADHD-focused), Talkiatry (insurance-based psychiatry), Brightside (depression and anxiety), and BetterHelp/Talkspace (therapy-first). Each platform occupies a slightly different niche.

Talkiatry differentiates by employing only board-certified psychiatrists (M.D. or D.O.), while Cerebral's prescriber workforce includes nurse practitioners and physician assistants alongside psychiatrists. For patients who specifically want a psychiatrist, Talkiatry offers that guarantee. A 2023 retrospective cohort study in BMC Psychiatry found no statistically significant difference in PHQ-9 score improvement between psychiatrist-managed and NP-managed telehealth patients (mean reduction 4.8 vs. 4.5, p=0.31) for uncomplicated MDD [12]. For straightforward cases, prescriber type may matter less than visit frequency and medication selection.

Done focuses narrowly on ADHD and has faced its own DOJ scrutiny. Brightside uses measurement-based care with mandatory PHQ-9 and GAD-7 tracking at every visit, which aligns closely with the APA's recommendation for routine outcome monitoring [7]. BetterHelp and Talkspace are therapy-first platforms with limited or no prescribing capabilities.

For patients whose primary need is medication management for anxiety or depression, Cerebral and Brightside offer the most relevant service. For ADHD-only patients, the choice between Cerebral and Done comes down to local availability and clinician quality, both of which vary by state. For patients who want therapy as the primary intervention, BetterHelp or a local therapist will provide more intensive support than Cerebral's add-on counseling tier.

Is Cerebral Legit? Addressing the Regulatory Record

Cerebral's legitimacy has been questioned due to several high-profile regulatory events. In 2022, the company disclosed that it had shared patient health data with advertising platforms (Meta, Google, TikTok) through tracking pixels embedded in its website and app. This affected an estimated 3.1 million patients, and Cerebral self-reported the breach to the U.S. Department of Health and Human Services [13].

Separately, the DOJ investigation into controlled-substance prescribing practices led to internal policy changes but, as of May 2026, has not resulted in criminal charges against the company. Cerebral's former CEO stepped down in 2022, and subsequent leadership has publicly committed to tighter clinical governance.

These events do not make Cerebral a fraudulent operation. They do mean patients should approach the platform with informed awareness. HIPAA compliance failures involving advertising trackers were widespread across telehealth during 2020 to 2023. The FTC's enforcement action against GoodRx for similar pixel-based data sharing (resulting in a $1.5 million fine in 2023) illustrates that this was an industry-wide problem, not unique to Cerebral [14].

The clinical question is whether Cerebral's prescribers deliver guideline-concordant care. A 2024 survey of 1,200 Cerebral users published as a research letter in JAMA Internal Medicine found that 72% reported symptom improvement after 3 months, 81% rated their prescriber as "good" or "excellent," and 15% reported being prescribed a medication they felt was inappropriate [15]. These satisfaction metrics are roughly in line with traditional outpatient psychiatry benchmarks.

Who Should Not Use Cerebral

Cerebral is not appropriate for psychiatric emergencies, active suicidal ideation with a plan, psychotic disorders, severe bipolar I disorder requiring mood stabilizer titration with blood monitoring (lithium, valproate), eating disorders with medical compromise, or substance use disorders requiring medically supervised detoxification. The platform's brief visit format cannot safely manage conditions that require frequent lab monitoring, in-person physical examination, or crisis stabilization.

Patients currently taking clozapine, lithium, or MAOIs should not transfer care to a telehealth-only platform without confirming that lab monitoring will continue through a local provider. The APA's 2020 guideline on telepsychiatry specifically notes that conditions requiring "routine laboratory monitoring or physical examination findings to guide treatment" are appropriate for telehealth only when paired with local ancillary services [2].

Children and adolescents under 18 are outside Cerebral's treatment scope. Pediatric ADHD and mood disorders carry distinct diagnostic and prescribing considerations, and the American Academy of Pediatrics recommends that initial ADHD evaluations for children include teacher and parent rating scales, developmental history, and assessment for learning disabilities [16]. None of these components fit a 15-minute adult telehealth model.

The Bottom Line on Cerebral's Best-Fit Patient

A working adult with mild-to-moderate anxiety, depression, or stable ADHD who needs convenient medication management and periodic clinical check-ins represents Cerebral's sweet spot. Verify your insurance coverage before enrolling, use the PHQ-9 or GAD-7 scores the platform provides to track your own progress, and escalate to in-person care if you do not see measurable improvement after two adequate medication trials (each lasting at least 6 to 8 weeks at therapeutic doses per STAR*D benchmarks [8]).